Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

Acacia Pharma Terug naar discussie overzicht

Acacia Pharma 2020

7.932 Posts
Pagina: «« 1 ... 274 275 276 277 278 ... 397 »» | Laatste | Omlaag ↓
  2. [verwijderd] 6 oktober 2020 16:49

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Sirlander schreef op 6 oktober 2020 16:35:

    [...]
    Ik dacht dat ergens in de prospectus stond dat ze die 25 milj. wel hebben opgenomen.
    Is hier op het forum gepasseerd...
    Klopt helemaal, was ik even vergeten.
  5. [verwijderd] 6 oktober 2020 16:52

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Astrix schreef op 6 oktober 2020 16:50:

    Daar zijn ze met hun PB
    toeval of niet. Had 1h geleden bericht gestuurd naar Gary om hun te feliciteren en om toch wat hun communicatieaandacht wat de verhogen
  6. [verwijderd] 6 oktober 2020 16:53

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    "Our first product BAR for ..., was launched in August and we are already registering product sales"

    Op zijn minst toch ene zot die het gekocht heeft dan ondertussen :)
  7. [verwijderd] 6 oktober 2020 16:55

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    •BYFAVO expected to be commercially available in the US before the end of the year

    This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

    Cambridge, UK and Indianapolis, US – 6 October 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, today announced that the US Drug Enforcement Administration (DEA) has designated its procedural sedative BYFAVO™ (remimazolam injection) as a Schedule IV medicine. This designation is the schedule for drugs with a low potential for abuse and low risk of dependence and is consistent with that granted to many other benzodiazepine drugs, including midazolam and diazepam (Valium®).
    BYFAVO received approval from the US Food and Drug Administration (FDA) on 2 July 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. Scheduling by DEA represents the final requirement for BYFAVO to be marketed in the US, with launch expected by the end of 2020.
    “We are grateful to DEA for its timely determination of the scheduling of BYFAVO and are excited to bring this novel product to the US market,” commented Mike Bolinder, Acacia Pharma’s CEO. “We will start the process of labeling and packaging our stock of commercial product immediately so that we can make BYFAVO available to patients as soon as possible. We anticipate the product being available for sale in the US prior to the end of the year. Our first product, BARHEMSYS® (amisulpride injection) for postoperative nausea & vomiting, was launched in August and we are already registering product sales. We are delighted to be able to provide these two medicines to physicians and their patients in the United States.”

  9. drulletje drie 6 oktober 2020 16:57

    • drulletje drie

      Lid sinds: 04 dec 2003

      Laatste bezoek: 09 mrt 2025

    • Aanbevelingen

      Ontvangen: 652

      Gegeven: 193

    •    Aantal posts: 19.220

    ·BYFAVO expected to be commercially available in the US before the end of the year

    This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
    Cambridge, UK and Indianapolis, US – 6 October 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, today announced that the US Drug Enforcement Administration (DEA) has designated its procedural sedative BYFAVO™ (remimazolam injection) as a Schedule IV medicine. This designation is the schedule for drugs with a low potential for abuse and low risk of dependence and is consistent with that granted to many other benzodiazepine drugs, including midazolam and diazepam (Valium®).
    BYFAVO received approval from the US Food and Drug Administration (FDA) on 2 July 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. Scheduling by DEA represents the final requirement for BYFAVO to be marketed in the US, with launch expected by the end of 2020.
    “We are grateful to DEA for its timely determination of the scheduling of BYFAVO and are excited to bring this novel product to the US market,” commented Mike Bolinder, Acacia Pharma’s CEO. “We will start the process of labeling and packaging our stock of commercial product immediately so that we can make BYFAVO available to patients as soon as possible. We anticipate the product being available for sale in the US prior to the end of the year. Our first product, BARHEMSYS® (amisulpride injection) for postoperative nausea & vomiting, was launched in August and we are already registering product sales. We are delighted to be able to provide these two medicines to physicians and their patients in the United States.”
  13. [verwijderd] 6 oktober 2020 17:00

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    was launched in August and we are already registering product sales. We are delighted to be able to provide these two medicines to physicians and their patients in the United States...

    Hij kon toch een beetje positiever zijn, genre already registering great product sales
  17. Mos1955 6 oktober 2020 17:03

    • Mos1955

      Lid sinds: 05 jan 2017

      Laatste bezoek: 09 mrt 2025

    • Aanbevelingen

      Ontvangen: 133

      Gegeven: 42

    •    Aantal posts: 559

    Het moest toch een keer gebeuren, die stijging. Maar kwam voor mij vanmiddag toch nog wel onverwacht.
  20. [verwijderd] 6 oktober 2020 17:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Madebeliefje schreef op 6 oktober 2020 17:02:

    En voor harry die op 1.90 wil kopen.
    Begin je volgende ritjes maar wat hoger, lager dan 2.12 gaat je niet meer lukken.
    Voor Harry niet alleen..had ze op kopen staan a 2 euro deze week maar helaas niet gehaald nondeju
7.932 Posts
Pagina: «« 1 ... 274 275 276 277 278 ... 397 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.097
AB InBev 2 5.525
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.863
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.772
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.764
Aedifica 3 923
Aegon 3.258 322.961
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.896
Agfa-Gevaert 14 2.051
Ahold 3.538 74.343
Air France - KLM 1.025 35.219
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.046
Alfen 16 25.019
Allfunds Group 4 1.510
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.502
AMG 971 134.005
AMS 3 73
Amsterdam Commodities 305 6.735
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.027
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.787
Arcelor Mittal 2.034 320.848
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.332
Aroundtown SA 1 220
Arrowhead Research 5 9.747
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.444
ASML 1.766 108.740
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 521
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.690
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.412